Scientists test new drug duo to stall tough lung cancer
NCT ID NCT03170206
Summary
This early-stage trial tested the safety and best dose of a two-drug combination for people with advanced lung cancer driven by a specific KRAS gene change. The study involved 34 adults and combined two oral medications, palbociclib and binimetinib, which work together to block different signals that tell cancer cells to grow. The main goals were to find a safe dose and see how well patients tolerated the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.